TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19356394
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (XM02) at 5 microg/kg
Study: 19356394
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (XM02) at 10 microg/kg
Study: 12044859
Drug: Vinpocetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinpocetine (20 mg in 500 ml saline)
Study: 12044859
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 ml saline)
Study: 7652726
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of magnesium
Study: 25978942
Drug: Mannitol cream
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol cream
Study: 25978942
Drug: Control cream
Normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control cream (without mannitol)
Study: 16475633
Drug: 0.5% hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% hyperbaric bupivacaine with fentanyl (20 microg) at a conventional high dose of 0.07 mg cm(‐1) (group 1)
Study: 16475633
Drug: 0.25% levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% levobupivacaine with fentanyl (20 microg) and epidural volume extension with 6 mL of saline (group 2)
Study: 11189545
Drug: Vacuum-assisted closure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacuum-assisted closure (V.A.C.) therapy
Study: 9728231
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate via metered dose inhaler (MDI)
Study: 3489445
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 500 mg twice a day and dipyridamole 75 mg three times a day
Study: 30950493
Drug: Azithromycin (20/mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (20/mg/kg single dose)
Study: 30316695
Drug: Propofol (1–4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1–4 mg kg−1)
Study: 30316695
Drug: Alfaxalone (0.5–2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone (0.5–2 mg kg−1)
Study: 23167308
Drug: MHBA grafted
Normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHBA grafted (TG) - buccal plate thickness ≤ 1 mm (TG-a)
Study: 23167308
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) - buccal plate thickness ≤ 1 mm (CG-a)
Study: 23167308
Drug: MHBA grafted
Normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MHBA grafted (TG) - buccal plate thickness > 1 mm (TG-b)
Study: 23167308
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) - buccal plate thickness > 1 mm (CG-b)
Study: 18844761
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (valsartan + hydrochlorothiazide)
Study: 18844761
Drug: Monotherapy (valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (valsartan alone)
Study: 16036126
Drug: Specimens immersed
Normalized name: SPECIMEN CONTAINER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specimens immersed in coffee solution
Study: 8942455
Drug: Social skills
Normalized name: Safety 1st Social Safety Pack KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social skills training with active drug supplementation
Study: 8942455
Drug: Supportive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive group therapy with active drug supplementation
Study: 8942455
Drug: Supportive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive group therapy with placebo supplementation
Study: 1840324
Drug: Teicoplanin 15
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin 15 mg/Kg iv
Study: 1840324
Drug: Teicoplanin 20
Normalized name: Teicoplanin 200 mg powder for solution for injection vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin 20 mg/Kg iv
Study: 1840324
Drug: Teicoplanin 25
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin 25 mg/Kg iv
Study: 7078016
Drug: Coded commercial
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coded commercial artificial tear solution 1
Study: 7078016
Drug: Coded commercial
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coded commercial artificial tear solution 2
Study: 7078016
Drug: Coded commercial
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coded commercial artificial tear solution 3
Study: 7078016
Drug: Coded commercial
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coded commercial artificial tear solution 4
Study: 28657703
Drug: Oral gel
Normalized name: Oral Gel
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral gel
Study: 28657703
Drug: Mouth spray
Normalized name: Moi-Stir Dry Mouth Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouth spray
Study: 26534729
Drug: Tailored practice
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored practice and patient plans; training sessions for practitioners in medication prescribing and behavioural change; regular patient recall system.
Study: 23432339
Drug: Melatonin administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin administered at 0.1 μg kg(‐1) h(‐1) for 2 hours
Study: 23432339
Drug: Population pharmacokinetics
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Population pharmacokinetics of melatonin
Study: 21450183
Drug: Oral extended-release
Normalized name: Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral extended-release oxybutynin 5 mg
Study: 15826410
Drug: Routine GP
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine GP treatment (Control)
Study: 9871862
Drug: Timolol hemihydrate
Normalized name: Timolol Hemihydrate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol hemihydrate 0.5% solution once daily
Study: 9871862
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate gel 0.5% once daily
Study: 8717212
Drug: rH‐EPO 9,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: rH‐EPO 9,000 IU intravenously daily
Study: 8717212
Drug: rH‐EPO (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: rH‐EPO (various doses)
Study: 2142293
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (IB), 250 micrograms inhalation solution
Study: 343728
Drug: Sulindac (300-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac (300-400 mg daily)
Study: 30269430
Drug: ISBB (Interscalene
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISBB (Interscalene Brachial Plexus Block) with 20 mL of 0.25% bupivacaine
Study: 30269430
Drug: SCBB (Supraclavicular
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCBB (Supraclavicular Brachial Plexus Block) with 20 mL of 0.25% bupivacaine
Study: 25969414
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) tablets, 60 mg (treatment A)
Study: 25969414
Drug: Powder formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder formulation delivered to the distal small bowel (treatment B)
Study: 25969414
Drug: Powder formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder formulation delivered to the ascending colon (treatment C)
Study: 25969414
Drug: Aqueous suspension
Normalized name: penicillin G procaine Injectable Suspension [Pen-Aqueous]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous suspension delivered to the ascending colon (treatment D)
Study: 25969414
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) tablets, 30 mg (treatment E)
Study: 25969414
Drug: Granulate formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulate formulation with fumaric acid 50 mg delivered to the ascending colon (treatment F)
Study: 21846929
Drug: Phenylephrine and
Normalized name: phenylephrine and ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine and epinephrine spray group
Study: 17882140
Drug: Tyrosine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine (400 mg)
Study: 17882140
Drug: Green Tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green Tea Extract (500 mg)
Study: 15630270
Drug: Concord grape
Normalized name: Concord Grape
DrugBank: Concord grape (DB10875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concord grape juice (CGJ) 5.5 ml/kg body weight/day for 8 weeks
Study: 9203227
Drug: Cortisol infusion
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol infusion (15 mg hydrocortisone sodium succinate over 120 min)
Study: 3295501
Drug: Moderate-dose methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Moderate-dose methotrexate
Study: 3295501
Drug: Both high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both high-dose and moderate-dose methotrexate
Study: 26280790
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group (28,000 IU)
Study: 12732840
Drug: Cremophor RH40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cremophor RH40 (600 mg 3 times daily)
Study: 3857359
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g CTM, given 4 times daily for 5 days (Group A)
Study: 3857359
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g CTM, given twice daily for 5 days (Group B)
Study: 24953794
Drug: Rituximab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (both dosing arms)
Study: 22180589
Drug: SmokeStop Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: SmokeStop Therapy (SST)
Study: 19904250
Drug: Double-dosed pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dosed pantoprazole (40 mg twice daily for 8 weeks)
Study: 19904250
Drug: Standard-dosed pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dosed pantoprazole (40 mg per day for 8 weeks and one blank tablet at night)
Study: 15954953
Drug: Propofol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (30 mg boluses every second minute)
Study: 15954953
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide (N2O, premedication with 30 mg propofol 5 min before, increased every other minute in 15% increments, max. 75%)
Study: 8835706
Drug: Citalopram (CIT)
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citalopram (CIT) 40 to 60 mg daily for 4 weeks
Study: 8835706
Drug: Citalopram (CIT)
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citalopram (CIT) with lithium carbonate (Li) 2 x 400 mg/day from days 29 to 35
Study: 8835706
Drug: Citalopram (CIT)
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citalopram (CIT) with lithium (Li) 800 mg/day from days 36 to 42
Study: 6486112
Drug: Breakfast containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakfast containing greater than 30 g fat
Study: 6486112
Drug: Breakfast containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakfast containing less than 15 g fat
Study: 6486112
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of C‐terminal octapeptide of cholecystokinin
Study: 26857421
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine care with additional low dose chest CT
Study: 25127679
Drug: Fecal immunochemical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal immunochemical tests (FITs), 3 tests (1/year for 3 years), cutoff ≥10 μg hemoglobin/g feces
Study: 18061756
Drug: Relaxation and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation and visualization therapy (RVT) for 24 consecutive days
Study: 9487345
Drug: Diffumal‐24 (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diffumal‐24 (once daily at 20.00 hours)
Study: 9487345
Drug: Theo‐Dur (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theo‐Dur (twice daily at 08.00 and 20.00 hours)
Study: 8149942
Drug: Buffered aspirin
Normalized name: Buffered Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buffered aspirin (700 mg)
Study: 8149942
Drug: Aspirin with
Normalized name: Bayer Aspirin with Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin with calcium carbonate (700 mg)
Study: 8149942
Drug: Aspirin with
Normalized name: Bayer Aspirin with Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin with caffeine (700 mg)
Study: 29519353
Drug: Etidronate (cyclical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate (cyclical 20 mg/kg for 2 weeks every 12 weeks)
Study: 16181528
Drug: Simple Western
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple Western medicine
Study: 14616429
Drug: Melatonin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (6 mg) alone
Study: 14616429
Drug: Melatonin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (6 mg) with caffeine (3 x 200 mg)
Study: 9282610
Drug: SL Nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SL Nifedipine 10 mg
Study: 9282610
Drug: SL Captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SL Captopril 25 mg
Study: 9282610
Drug: IV Metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Metoprolol 15 mg
Study: 1658591
Drug: LAK cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAK cells injected i.a on days 10, 14, and 21 after operation with IL-2 injections during 3 weeks.
Study: 1658591
Drug: Adriamycin treatment
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin treatment only (Control group).
Study: 23566246
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg daily for two months followed by an individually matched dose of 10 or 20 mg/day (group A)
Study: 23566246
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group B) treated according to current recommendations without statin therapy
Study: 18830045
Drug: Vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K2 treatment
Study: 10047932
Drug: Immediate-release carbidopa/levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release carbidopa/levodopa (Sinemet, IR-CL)
Study: 10047932
Drug: Controlled-release carbidopa/levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release carbidopa/levodopa (Sinemet CR, CR-CL)
Study: 8559497
Drug: rHuEpo treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEpo treatment
Study: 8559497
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no rHuEpo treatment)
Study: 30860474
Drug: Thymopentin (TP5)
Normalized name: thymopentin
DrugBank: Thymopentin (DB11996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin (TP5) add-on therapy for 24 weeks with entecavir (ETV) and peginterferon alfa-2a (PegIFN alpha-2a)
Study: 23388507
Drug: Remifentanil (0-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0-10 ng ml(‐1)) and sevoflurane (0.3-3.4 vol.%)
Study: 11903835
Drug: Cisapride 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 0.2 mg/kg four times a day for 7 days
Study: 2906367
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg iv dose administered by constant-rate infusion over 30 min
Study: 2906367
Drug: Oral doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doses of 10 mg, 20 mg, and 40 mg
Study: 2906367
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg iv dose, 10 mg oral dose, 20 mg oral dose, 40 mg oral dose
Study: 25535011
Drug: SSRI medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI medication regimen
Study: 23087419
Drug: Subconjunctival bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subconjunctival bevacizumab (2.5 mg in 0.1 ml injections)
Study: 18212687
Drug: Combined intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combined intra-arterial (IA) plus intramuscular (IM) administration of autologous bone marrow mononuclear cells (BMC)
Study: 18212687
Drug: Sole intramuscular
Normalized name: English sole
DrugBank: English sole (DB10904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sole intramuscular (IM) administration of autologous bone marrow mononuclear cells (BMC)
Study: 18212687
Drug: Combined IA+IM
Normalized name: magnesium aluminum silicate type Ia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined IA+IM administration of autologous BMC
Study: 12454805
Drug: Nurse-led cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led cognitive-behavioral treatment (CBT) pain management program
Study: 10322244
Drug: Cimetidine 1600
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine 1600 mg
Study: 28984096
Drug: Ketamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (1 mg/kg IV and 0.5 mg/kg/h)
Study: 25349864
Drug: Inhalation technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation technique with spacer
Study: 25349864
Drug: Inhalation technique
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation technique without spacer
Study: 23565943
Drug: Monosodium glutamate
Normalized name: Monosodium Glutamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monosodium glutamate (MSG) intake (150 mg/kg)
Study: 23565943
Drug: Placebo (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (24 mg/kg NaCl)
Study: 16403616
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with standardized mite extracts (D.p. and D.f.)
Study: 8694295
Drug: 4.0 mg
Normalized name: LORAZEPAM 4.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.0 mg of intrathecal morphine (Group MS)
Study: 1286050
Drug: EEP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EEP chemotherapy (Etoposide + Epirubicin + Cisplatin)
Study: 1286050
Drug: FEM chemotherapy
Normalized name: Fem Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEM chemotherapy (Control)
Study: 1286050
Drug: EEP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EEP chemotherapy
Study: 3890307
Drug: CAP combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAP combination chemotherapy
Study: 3890307
Drug: CMFVP combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMFVP combination chemotherapy
Study: 3890307
Drug: CAP combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAP combination chemotherapy (as second-line treatment)
Study: 31145885
Drug: Early insertion
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early insertion of ENG implant
Study: 31145885
Drug: Delayed insertion
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed insertion of ENG implant
Study: 30307302
Drug: Dairy products
Normalized name: Food - Dairy Products, Whey, Cow's Milk
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dairy products enriched with calcium and vitamin D (250 ml daily)
Study: 1481657
Drug: Topical nasal
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nasal decongestant in different formulations (varied viscosities)
Study: 18207532
Drug: Preoperative only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative only protocol (single dose of cefazolin IV)
Study: 18207532
Drug: Preoperative with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative with extended postoperative antibiotic protocol (single dose of cefazolin IV followed by cefazolin IV every 8 hours for 3 days and oral cephalexin every 6 hours for 7 days)
Study: 8877348
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg daily for up to three months
Study: 31672146
Drug: liraglutide 3
Normalized name: liraglutide 3.6 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide 3 mg
Study: 29680881
Drug: Baricitinib 4
Normalized name: baricitinib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 4 mg daily
Study: 27028914
Drug: Baricitinib 2
Normalized name: baricitinib 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 2 mg daily
Study: 12399209
Drug: Meningococcal A/C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal A/C plain polysaccharide vaccine (Mps)
Study: 12399209
Drug: Meningococcal A/C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal A/C polysaccharide-diphtheria toxoid conjugate vaccine (Mcj)
Study: 7838584
Drug: Morphine (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.075 mg/kg)